New cancer drug targets two proteins at once in early trial
NCT ID NCT07067567
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tests a new drug called AK146D1 in 200 adults with advanced solid tumors that have worsened after standard treatments. The drug is designed to attach to two proteins (Trop2 and Nectin4) on cancer cells and deliver a toxic payload. The main goals are to check safety and find the right dose, while also looking for signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK146D1 (a bispecific antibody-drug conjugate targeting Trop2 and Nectin4 proteins on cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial, so the drug may not be safe or effective. Side effects could be serious, and it is not yet known if it will shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SunYat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Email: •••••@•••••